Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.
about
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitisEmerging drugs for uveitisCurrent stage in inflammatory bowel disease: What is next?Immunomodulatory drugs and their application to the management of canine immune-mediated disease.The fundamental basis of inflammatory bowel disease.Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.Pharmacogenetics and inflammatory bowel disease: progress and prospects.Biologics in inflammatory bowel disease: how much progress have we made?Emerging drugs for the treatment of ulcerative colitisImmunogenicity of biological agents in inflammatory bowel disease.Clinical application of human CD4+ CD25+ regulatory T cells for the treatment of inflammatory bowel diseases.Molecular targets in the treatment of alcoholic hepatitis.Evolving knowledge and therapy of inflammatory bowel disease.Emerging biological treatments in inflammatory bowel diseases.Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion moleculesUpdate in the treatment of paediatric ulcerative colitis.Safety of biologic therapy.Treatment of inflammatory bowel disease: a review of medical therapy.Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis.Biologic targeting in the treatment of inflammatory bowel diseases.Therapeutic options in acute severe ulcerative colitis.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.T-cell-directed therapies in inflammatory bowel diseases.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Cytokine blockade in inflammatory bowel diseases.Biological therapies for inflammatory bowel disease: controversies and future options.Targeted immunotherapy trials for idiopathic inflammatory myopathies.The role of biologic agents in the management of non-infectious uveitis.The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease.Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation.Glucocorticoids and the emerging importance of T cell subsets in steroid refractory diseases.Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.
P2860
Q24242681-DD5A1B6C-F909-4B16-A01A-E05BFB615F53Q24630848-C63FE4E9-349E-43ED-9060-4CAA127FADDAQ26777429-C86FC5EA-24A1-448E-B6D0-08EDE85942E9Q33393823-F4413A2D-A126-4E3E-B658-BC24647D9E02Q35649436-2688F5C1-CAD0-4341-BA5F-924EF0FD8FE1Q35769121-7256132C-D5E2-459C-A256-D039D681E8EAQ35787609-05142E77-1AC6-4E13-89F4-B84FDEA23227Q35861158-CA1E6914-B894-43F4-80DA-6AF79659AC96Q36039436-1C1F2E41-A0F9-4416-BE98-70630DD93151Q36113933-4F16C2AD-655A-4279-949F-7C310E1B38B4Q36150414-9A08B7B3-57C4-4417-A28D-CBE73C5C70E1Q36351877-34A6E254-3FC2-4559-A2BC-C49AE526A049Q36414506-BCB6FF4A-D909-4D19-8511-FA24513143D7Q36478109-9C34E475-AD24-4301-9D3C-ED55BB70F300Q36579737-D0C139EC-9179-4662-BAE6-DD709FB477C4Q36613876-D3BB4966-E3E2-4C64-9FDC-10C69C99D2B9Q36737339-04BCF5E2-09DD-47F2-B982-B6406F2576A5Q37058862-8BC9A749-18EE-454E-9DEA-B9F697AFEAC7Q37060182-D512A4D2-FFC2-4308-8CCF-47C75E4BD3AEQ37303206-D2524F61-0E0E-4522-80E7-EB27A8F5E4BCQ37345935-070DDDD2-6C87-4EFA-84A6-6B00DFE3BA29Q37680981-D6CC8A19-7452-46DD-8599-11838895C4A9Q37720783-F54AC0D0-99E7-473C-BD15-E0AC45BCE248Q37847059-D562A583-6D8F-49FF-B267-9A5565E7B789Q37952792-99029D72-8C6E-45F5-8E2D-E398DCEA9226Q37960183-71AE6A97-1C00-4C8C-A9EB-B3A6EACEA362Q38023207-3A783946-3442-4DA4-8248-24E36CA005BDQ38025152-E6E0623F-C435-4D99-B4DF-0FEF8EBB9BDEQ38132555-9D5F3A82-A5E7-4E4A-8073-2620224BC1B0Q42684792-FA6B2692-04B8-4932-8886-A9DB389F9BA3Q44722785-818372ED-C7CF-4D47-9D63-0B4CF0E2D754Q51802719-A5E52F50-FF41-4A88-9677-8A00A27DED93Q54563945-F839EC98-5DB6-4AE3-90AF-27502DFD1EED
P2860
Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Basiliximab (anti-CD25) in com ...... -resistant ulcerative colitis.
@en
Basiliximab
@nl
type
label
Basiliximab (anti-CD25) in com ...... -resistant ulcerative colitis.
@en
Basiliximab
@nl
prefLabel
Basiliximab (anti-CD25) in com ...... -resistant ulcerative colitis.
@en
Basiliximab
@nl
P2093
P2860
P1476
Basiliximab (anti-CD25) in com ...... -resistant ulcerative colitis.
@en
P2093
C S J Probert
J Anderson
J Smithson
M Moorghen
M R Norman
N A Shepherd
R F Harvey
S D Hearing
P2860
P356
10.1046/J.1365-2036.2003.01639.X
P407
P577
2003-07-01T00:00:00Z